Patient characteristics of the study cohort
| Parameters/time point of relapse/progression after CAR-Ts . | All patients . | Early relapse . | Intermediate relapse . | Late relapse . | P value . |
|---|---|---|---|---|---|
| Patients, n (%) | 92 (100) | 48 (52) | 24 (26) | 20 (22) | – |
| Age at lymphoma dx (range), y (available for 91/92 cases) | 61 (20-78) | 57 (20-78) | 62 (27-77) | 63 (37-77) | .842 |
| Sex, n (%) | |||||
| Male | 62 (67) | 32 (67) | 16 (67) | 14 (70) | .961 |
| Female | 30 (33) | 16 (33) | 8 (33) | 6 (30) | |
| Lymphoma types, n (%) | |||||
| DLBCL de novo | 59 (64) | 32 (67) | 16 (67) | 11 (55) | .629 |
| GCB | 19 (21) | 7 (15) | 7 (29) | 5 (25) | .306 |
| Non-GCB | 16 (17) | 11 (23) | 4 (17) | 1 (5) | .205 |
| NOS | 24 (26) | 14 (29) | 5 (21) | 5 (25) | .744 |
| DLBCL transformed from indolent lymphoma | 20 (22) | 7 (15) | 5 (21) | 8 (40) | .068 |
| HGBCL with MYC and BCL2 rearrangement | 6 (7) | 5 (10) | 1 (4) | 0 (0) | .246 |
| HGBCL, NOS | 4 (4) | 1 (2) | 2 (8) | 1 (5) | .740 |
| HGBCL with 11q deletion | 1 (1) | 1 (2) | 0 (0) | 0 (0) | .629 |
| PMBCL | 1 (1) | 1 (2) | 0 (0) | 0 (0) | .629 |
| TCRLBCL | 1 (1) | 1 (2) | 0 (0) | 0 (0) | .629 |
| Median time from dx to BsAb (range), mo | 20 (4-151) | 13 (4-125) | 22 (12-105) | 36 (14-151) | <.001 |
| Lymphodepletion before CAR-T infusion, n (%) | |||||
| Fludarabine/cyclophosphamide | 90 (98) | 46 (96) | 24 (100) | 20 (100) | .392 |
| Bendamustine | 2 (2) | 2 (4) | 0 (0) | 0 (0) | .392 |
| Therapies before BsAb, n (%) | |||||
| Median tx lines before BsAb (range), n (available for 91/92 cases) | 4 (2-9) | 3 (2-9) | 4 (2-9) | 4.5 (2-8) | .040 |
| Anti-CD20/anthra-based regiment | 89 (97) | 47 (98) | 24 (100) | 18 (90) | .142 |
| Platinum-based salvage regimen | 73 (79) | 38 (79) | 19 (79) | 16 (80) | .997 |
| Benda/ritux ± polatuz ved | 36 (39) | 17 (35) | 11 (46) | 8 (40) | .692 |
| Benda within last 6 months before BsAb | 18 (20) | 13 (27) | 5 (21) | 0 (0) | .037 |
| Tafasitamab/lenalidomide | 15 (16) | 9 (19) | 2 (8) | 4 (20) | .466 |
| PD-1 inhibitor, n | 2 (2) | 0 (0) | 0 (0) | 2 (10) | .025 |
| Ibrutinib | 5 (5) | 3 (6) | 0 (0) | 2 (40) | .324 |
| Previous autologous SCT | 23 (25) | 9 (19) | 5 (21) | 9 (45) | .064 |
| Previous allogeneic SCT | 5 (5) | 1 (2) | 2 (8) | 3 (15) | .324 |
| Bulky dz (>7.5 cm) before BsAb | 25 (27) | 15 (31) | 6 (25) | 4 (20) | .667 |
| Extranodal lesions before BsAbs | 52 (57) | 30 (63) | 13 (54) | 9 (45) | .400 |
| Median LDH U/L before BsAbs (range), n | 367 (164-3600) | 380 (164-2505) | 383 (170-3600) | 326 (164-1799) | .406 |
| IPI score before BsAb, n (%) | |||||
| IPI low (0-1) | 15 (16) | 8 (17) | 2 (8) | 5 (25) | .328 |
| IPI low-int (2) | 15 (16) | 8 (17) | 2 (8) | 5 (25) | .356 |
| IPI high-int (3) | 33 (36) | 14 (29) | 11 (46) | 8 (40) | .346 |
| IPI high (4-5) | 29 (32) | 18 (38) | 9 (38) | 2 (10) | .064 |
| Refractory to last tx, n (%) | 54 (59) | 36 (75) | 12 (50) | 6 (30) | .002 |
| Types of BsAb administered, n (%) | |||||
| Glofitamab | 85 (92) | 43 (90) | 22 (92) | 20 (100) | .229 |
| Epcoritamab | 6 (7) | 5 (10) | 1 (4) | 0 (0) | |
| Mosunetuzumab | 1 (1) | 0 (0) | 1 (4) | 0 (0) | |
| Parameters/time point of relapse/progression after CAR-Ts . | All patients . | Early relapse . | Intermediate relapse . | Late relapse . | P value . |
|---|---|---|---|---|---|
| Patients, n (%) | 92 (100) | 48 (52) | 24 (26) | 20 (22) | – |
| Age at lymphoma dx (range), y (available for 91/92 cases) | 61 (20-78) | 57 (20-78) | 62 (27-77) | 63 (37-77) | .842 |
| Sex, n (%) | |||||
| Male | 62 (67) | 32 (67) | 16 (67) | 14 (70) | .961 |
| Female | 30 (33) | 16 (33) | 8 (33) | 6 (30) | |
| Lymphoma types, n (%) | |||||
| DLBCL de novo | 59 (64) | 32 (67) | 16 (67) | 11 (55) | .629 |
| GCB | 19 (21) | 7 (15) | 7 (29) | 5 (25) | .306 |
| Non-GCB | 16 (17) | 11 (23) | 4 (17) | 1 (5) | .205 |
| NOS | 24 (26) | 14 (29) | 5 (21) | 5 (25) | .744 |
| DLBCL transformed from indolent lymphoma | 20 (22) | 7 (15) | 5 (21) | 8 (40) | .068 |
| HGBCL with MYC and BCL2 rearrangement | 6 (7) | 5 (10) | 1 (4) | 0 (0) | .246 |
| HGBCL, NOS | 4 (4) | 1 (2) | 2 (8) | 1 (5) | .740 |
| HGBCL with 11q deletion | 1 (1) | 1 (2) | 0 (0) | 0 (0) | .629 |
| PMBCL | 1 (1) | 1 (2) | 0 (0) | 0 (0) | .629 |
| TCRLBCL | 1 (1) | 1 (2) | 0 (0) | 0 (0) | .629 |
| Median time from dx to BsAb (range), mo | 20 (4-151) | 13 (4-125) | 22 (12-105) | 36 (14-151) | <.001 |
| Lymphodepletion before CAR-T infusion, n (%) | |||||
| Fludarabine/cyclophosphamide | 90 (98) | 46 (96) | 24 (100) | 20 (100) | .392 |
| Bendamustine | 2 (2) | 2 (4) | 0 (0) | 0 (0) | .392 |
| Therapies before BsAb, n (%) | |||||
| Median tx lines before BsAb (range), n (available for 91/92 cases) | 4 (2-9) | 3 (2-9) | 4 (2-9) | 4.5 (2-8) | .040 |
| Anti-CD20/anthra-based regiment | 89 (97) | 47 (98) | 24 (100) | 18 (90) | .142 |
| Platinum-based salvage regimen | 73 (79) | 38 (79) | 19 (79) | 16 (80) | .997 |
| Benda/ritux ± polatuz ved | 36 (39) | 17 (35) | 11 (46) | 8 (40) | .692 |
| Benda within last 6 months before BsAb | 18 (20) | 13 (27) | 5 (21) | 0 (0) | .037 |
| Tafasitamab/lenalidomide | 15 (16) | 9 (19) | 2 (8) | 4 (20) | .466 |
| PD-1 inhibitor, n | 2 (2) | 0 (0) | 0 (0) | 2 (10) | .025 |
| Ibrutinib | 5 (5) | 3 (6) | 0 (0) | 2 (40) | .324 |
| Previous autologous SCT | 23 (25) | 9 (19) | 5 (21) | 9 (45) | .064 |
| Previous allogeneic SCT | 5 (5) | 1 (2) | 2 (8) | 3 (15) | .324 |
| Bulky dz (>7.5 cm) before BsAb | 25 (27) | 15 (31) | 6 (25) | 4 (20) | .667 |
| Extranodal lesions before BsAbs | 52 (57) | 30 (63) | 13 (54) | 9 (45) | .400 |
| Median LDH U/L before BsAbs (range), n | 367 (164-3600) | 380 (164-2505) | 383 (170-3600) | 326 (164-1799) | .406 |
| IPI score before BsAb, n (%) | |||||
| IPI low (0-1) | 15 (16) | 8 (17) | 2 (8) | 5 (25) | .328 |
| IPI low-int (2) | 15 (16) | 8 (17) | 2 (8) | 5 (25) | .356 |
| IPI high-int (3) | 33 (36) | 14 (29) | 11 (46) | 8 (40) | .346 |
| IPI high (4-5) | 29 (32) | 18 (38) | 9 (38) | 2 (10) | .064 |
| Refractory to last tx, n (%) | 54 (59) | 36 (75) | 12 (50) | 6 (30) | .002 |
| Types of BsAb administered, n (%) | |||||
| Glofitamab | 85 (92) | 43 (90) | 22 (92) | 20 (100) | .229 |
| Epcoritamab | 6 (7) | 5 (10) | 1 (4) | 0 (0) | |
| Mosunetuzumab | 1 (1) | 0 (0) | 1 (4) | 0 (0) | |
Indicated parameters in the respective cohorts. The P values are obtained using the Fisher exact test for categorical data and Mann-Whitney U test for metric data.
anthra, anthracycline; anti-CD20, antibody directed against the surface protein CD20; Benda, bendamustine; dx, diagnosis; dz, disease; HGBCL, high-grade BCL; int, intermediate; NOS, not otherwise specified; PD-1, programmed cell death protein 1; PMBCL, primary mediastinal LBCL; polatuz ved, polatuzumab vedotin; ritux, rituximab; TCRLBCL, T-cell/histiocyte-rich LBCL; tx, therapy.